GlassScriptPhysician profile
Ahmed Ali Khalid
NPI 1649234121
$8,274.86
in general payments reported to CMS, 2019-2025
18 companies · $395 in 2025
The $395 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,557 · 2021: $51.90 · 2022: $208 · 2023: $1,912 · 2024: $151 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,625 · Food and Beverage: $833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,625.00 |
| Food and Beverage | $832.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $5,619.33 | 2019-2025 | |
| Beigene USA, INC. | $1,645.26 | 2023 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $293.87 | 2019-2025 | Breyanzi, Opdivo |
| Boston Scientific Corporation | $167.60 | 2022-2023 | |
| Genentech USA, INC. | $133.15 | 2025 | Tecentriq |
| Getinge USA Sales, LLC | $114.83 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $87.35 | 2021-2024 | Dupixent |
| Abbvie INC. | $43.07 | 2023-2025 | |
| Ethicon US, LLC | $28.93 | 2023 | Certus 140 |
| Janssen Biotech, INC. | $28.33 | 2023-2025 | Tecvayli, Darzalex |
| Daiichi Sankyo INC. | $26.63 | 2025 | Enhertu |
| Glaxosmithkline, LLC. | $16.57 | 2024 | Ojjaara |
| Pfizer INC. | $16.27 | 2025 | |
| Celgene Corporation | $14.28 | 2023 | Pomalyst |
| Kite Pharma, INC. | $13.85 | 2023 | Yescarta |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $13.62 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Khalid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.